An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

On Monday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.01 which represents a slight increase of $0.60 or 1.21% from the prior close of $49.41. The stock opened at ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

A groundbreaking lung cancer screening project co-led by the University of Kentucky Markey Cancer Center and the University of Colorado (CU) Cancer ...

Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...

Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is ...

Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) ...

A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its ...

An attorney for Bristol Myers Squibb on Friday urged a New York federal judge to dismiss a $6.4 billion action against the pharmaceutical giant, claiming the plaintiff has no subject matter ...